Thalys Medical Technology Group Corporation (SHA:603716)
China · Delayed Price · Currency is CNY 22.49
+0.11 (0.49%)
Feb 4, 2026, 3:00 PM CST
SHA:603716 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,243 | 1,806 | 1,992 | 2,293 | 2,590 | 2,124 |
Other Revenue | 5.14 | 5.14 | 14.53 | 16.05 | 9.99 | 1.49 |
| 1,248 | 1,811 | 2,006 | 2,309 | 2,600 | 2,125 | |
Revenue Growth (YoY) | -34.22% | -9.74% | -13.10% | -11.19% | 22.30% | 16.10% |
Cost of Revenue | 1,015 | 1,482 | 1,616 | 1,860 | 2,057 | 1,639 |
Gross Profit | 232.42 | 328.54 | 389.74 | 448.96 | 542.74 | 486.83 |
Selling, General & Admin | 261.55 | 299.75 | 327.98 | 336.23 | 339.89 | 260.99 |
Research & Development | 44.88 | 46.53 | 43.02 | 29.32 | 35.47 | 19.49 |
Other Operating Expenses | 8.71 | 7.91 | 9.48 | 10.7 | 12.61 | 9.87 |
Operating Expenses | 316.86 | 315.66 | 408.65 | 464.47 | 447.93 | 312.52 |
Operating Income | -84.44 | 12.88 | -18.91 | -15.51 | 94.81 | 174.31 |
Interest Expense | -41.76 | -57.68 | -76.19 | -98.76 | -82.78 | -57.72 |
Interest & Investment Income | 6.47 | 3.84 | 7.51 | 19.36 | 7.95 | 10.98 |
Currency Exchange Gain (Loss) | -0.55 | -0.55 | -3.04 | -7.62 | 0.4 | -0.22 |
Other Non Operating Income (Expenses) | -4.68 | -5.38 | -52.67 | -5.37 | -18.36 | -14.89 |
EBT Excluding Unusual Items | -124.96 | -46.89 | -143.3 | -107.89 | 2.03 | 112.46 |
Impairment of Goodwill | -22.43 | -22.43 | -26.61 | -12.23 | - | -0.01 |
Gain (Loss) on Sale of Investments | -20.43 | -68.01 | -11.3 | -31.8 | -25.66 | - |
Gain (Loss) on Sale of Assets | -8.78 | -9.37 | -11.83 | -0.02 | 0.4 | -0.16 |
Asset Writedown | -0.3 | - | - | -6.95 | -0.72 | -0.46 |
Other Unusual Items | -1.47 | -1.59 | 0.54 | -32.82 | -0.15 | -3.75 |
Pretax Income | -178.36 | -148.3 | -192.5 | -191.71 | -24.11 | 108.08 |
Income Tax Expense | 60.67 | 45.09 | -35.73 | -1.46 | 14.27 | 26.05 |
Earnings From Continuing Operations | -239.03 | -193.39 | -156.78 | -190.25 | -38.38 | 82.03 |
Minority Interest in Earnings | -1.43 | -15.85 | -1.8 | 36.52 | -11.13 | -24.47 |
Net Income | -240.46 | -209.24 | -158.57 | -153.73 | -49.51 | 57.56 |
Net Income to Common | -240.46 | -209.24 | -158.57 | -153.73 | -49.51 | 57.56 |
Net Income Growth | - | - | - | - | - | -47.87% |
Shares Outstanding (Basic) | 191 | 192 | 193 | 195 | 198 | 198 |
Shares Outstanding (Diluted) | 191 | 192 | 193 | 195 | 198 | 198 |
Shares Change (YoY) | -4.89% | -0.73% | -0.62% | -1.73% | -0.23% | 0.66% |
EPS (Basic) | -1.26 | -1.09 | -0.82 | -0.79 | -0.25 | 0.29 |
EPS (Diluted) | -1.26 | -1.09 | -0.82 | -0.79 | -0.25 | 0.29 |
EPS Growth | - | - | - | - | - | -48.21% |
Free Cash Flow | 59.77 | 76.39 | 85.06 | -26.52 | -193.71 | -117.76 |
Free Cash Flow Per Share | 0.31 | 0.40 | 0.44 | -0.14 | -0.98 | -0.59 |
Gross Margin | 18.63% | 18.14% | 19.43% | 19.45% | 20.88% | 22.91% |
Operating Margin | -6.77% | 0.71% | -0.94% | -0.67% | 3.65% | 8.20% |
Profit Margin | -19.27% | -11.56% | -7.90% | -6.66% | -1.90% | 2.71% |
Free Cash Flow Margin | 4.79% | 4.22% | 4.24% | -1.15% | -7.45% | -5.54% |
EBITDA | -63.57 | 47.3 | 33.58 | 45.23 | 166.83 | 250.9 |
EBITDA Margin | -5.10% | 2.61% | 1.67% | 1.96% | 6.42% | 11.80% |
D&A For EBITDA | 20.87 | 34.42 | 52.5 | 60.74 | 72.01 | 76.59 |
EBIT | -84.44 | 12.88 | -18.91 | -15.51 | 94.81 | 174.31 |
EBIT Margin | -6.77% | 0.71% | -0.94% | -0.67% | 3.65% | 8.20% |
Effective Tax Rate | - | - | - | - | - | 24.10% |
Revenue as Reported | 1,248 | 1,811 | 2,006 | 2,309 | 2,600 | 2,125 |
Advertising Expenses | - | - | - | - | 12.89 | 5.43 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.